MA33023B1 - Formulation d'anticorps - Google Patents

Formulation d'anticorps

Info

Publication number
MA33023B1
MA33023B1 MA33984A MA33984A MA33023B1 MA 33023 B1 MA33023 B1 MA 33023B1 MA 33984 A MA33984 A MA 33984A MA 33984 A MA33984 A MA 33984A MA 33023 B1 MA33023 B1 MA 33023B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical formulations
antibodies
formulation
aggregate
beta
Prior art date
Application number
MA33984A
Other languages
Arabic (ar)
English (en)
Inventor
Joachim Momm
Hans-Joachim Wallny
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40637230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33023(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA33023B1 publication Critical patent/MA33023B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention porte sur des formulations pharmaceutiques, en particulier sur de nouvelles formulations pharmaceutiques dans lesquelles l'ingrédient actif comprend des anticorps humains dirigés contre l'interleukine I bêta humaine (IL-²1), en particulier l'anticorps ACZ885, sur des formulations pharmaceutiques qui sont stables et exemptes d'agrégat lors du stockage et de l'administration.
MA33984A 2008-12-10 2009-12-09 Formulation d'anticorps MA33023B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08170884A EP2196476A1 (fr) 2008-12-10 2008-12-10 Formulation d'anticorps
PCT/EP2009/066675 WO2010066762A1 (fr) 2008-12-10 2009-12-09 Formulation d'anticorps

Publications (1)

Publication Number Publication Date
MA33023B1 true MA33023B1 (fr) 2012-02-01

Family

ID=40637230

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33984A MA33023B1 (fr) 2008-12-10 2009-12-09 Formulation d'anticorps

Country Status (31)

Country Link
US (3) US20110236398A1 (fr)
EP (4) EP2196476A1 (fr)
JP (6) JP6143416B2 (fr)
KR (2) KR20170044211A (fr)
CN (3) CN104399076B (fr)
AU (1) AU2009324371B2 (fr)
BR (1) BRPI0922730A2 (fr)
CA (1) CA2745938C (fr)
CL (1) CL2011001406A1 (fr)
CO (1) CO6361952A2 (fr)
CY (2) CY1117735T1 (fr)
DK (2) DK3072906T3 (fr)
EC (1) ECSP11011192A (fr)
ES (2) ES2900624T3 (fr)
HR (2) HRP20211899T1 (fr)
HU (2) HUE028408T2 (fr)
IL (3) IL264316B2 (fr)
LT (1) LT3072906T (fr)
MA (1) MA33023B1 (fr)
MX (1) MX2011006242A (fr)
MY (2) MY157772A (fr)
NZ (1) NZ592918A (fr)
PE (1) PE20120342A1 (fr)
PL (2) PL2376533T3 (fr)
PT (2) PT2376533T (fr)
RU (2) RU2745601C2 (fr)
SI (2) SI3072906T1 (fr)
SM (1) SMT201600222B (fr)
TN (1) TN2011000229A1 (fr)
WO (1) WO2010066762A1 (fr)
ZA (1) ZA201103362B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196476A1 (fr) * 2008-12-10 2010-06-16 Novartis Ag Formulation d'anticorps
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
CN107496917B (zh) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
SG183443A1 (en) 2010-03-01 2012-09-27 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
MX2012013586A (es) 2010-05-28 2013-01-24 Novo Nordisk As Composiciones multi-dosis estables que comprenden un anticuerpo y un conservante.
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US8795658B2 (en) 2010-09-17 2014-08-05 Baxter International Inc. Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral pH
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
TWI719112B (zh) 2011-03-16 2021-02-21 賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
FI123630B (fi) 2011-10-24 2013-08-30 Teknologian Tutkimuskeskus Vtt Menetelmä NFC-kalvojen valmistamiseksi alustoille
AP2014007680A0 (en) 2011-12-02 2014-06-30 Novartis Ag Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
JP6345123B2 (ja) * 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
PT2825037T (pt) * 2012-03-16 2019-08-07 Regeneron Pharma Animais não humanos que expressam sequências de imunoglobulinas sensíveis ao ph
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2834259A4 (fr) 2012-04-02 2016-08-24 Moderna Therapeutics Inc Polynucléotides modifiés
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
HK1208231A1 (en) * 2012-09-20 2016-02-26 Morphosys Ag Treatment for rheumatoid arthritis
WO2014078502A1 (fr) * 2012-11-16 2014-05-22 Novartis Ag Utilisation d'anticorps de liaison à il-1-bêta pour le traitement de la maladie artérielle périphérique
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
UY35460A (es) 2013-03-15 2014-10-31 Bayer Healthcare Llc Formulaciones de anticuerpos anti-receptor de prolactina
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (fr) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucléotides codant pour un récepteur de lipoprotéines de faible densité
WO2015181757A1 (fr) * 2014-05-28 2015-12-03 Nono Inc. Formulation lyophilisée de tat-nr2b9c avec capteur d'acétylation
BR112017003419A2 (pt) * 2014-09-03 2017-11-28 Medimmune Ltd formulação de anticorpo anti-il-4r-alfa estável
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
WO2016077451A1 (fr) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anticorps anti-endogline et leurs utilisations
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
DK3386541T3 (da) 2015-12-07 2020-09-28 Merck Patent Gmbh Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab
CN109415440B (zh) * 2016-06-27 2022-12-06 莫佛塞斯公司 抗-cd19抗体制剂
AU2017298656A1 (en) * 2016-07-21 2019-02-07 Novartis Ag Use of the IL-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis
KR102546471B1 (ko) * 2016-09-27 2023-06-21 프레제니우스 카비 도이치란트 게엠베하 액상의 약학 조성물
SG10201912529SA (en) 2016-11-18 2020-02-27 Astellas Pharma Inc Novel anti-human muc1 antibody fab fragment
KR20200019865A (ko) * 2017-06-22 2020-02-25 노파르티스 아게 암 치료에 사용하기 위한 il-1베타 결합 항체
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
MX2020002813A (es) * 2017-09-13 2020-07-21 Novartis Ag Uso de anticuerpos de union a il-1b para el tratamiento de la hepatitis alcoholica.
WO2019180261A1 (fr) * 2018-03-23 2019-09-26 AbbVie Deutschland GmbH & Co. KG Formulations aqueuses stables d'anticorps anti-tau
MX2020012351A (es) 2018-05-17 2021-01-29 Astellas Pharma Inc Complejo que tiene fragmento fab de anticuerpo anti-muc1 de humano, enlazador peptido y/o ligando.
EP3865154A4 (fr) 2018-10-10 2022-11-09 Astellas Pharma Inc. Composition pharmaceutique contenant un complexe de fragment fab d'anticorps au site anti-humain marqué
SG11202108627SA (en) * 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
CN113967195A (zh) * 2020-07-22 2022-01-25 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体冻干制剂及其制备方法
US20240052026A1 (en) * 2020-12-22 2024-02-15 Bio-Thera Solutions, Ltd. Stable antibody formulation, preparation method therefor, and applications thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (fr) 1993-07-09 1995-01-19 Smithkline Beecham Corporation ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
TWI260321B (en) 1999-09-22 2006-08-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
CN101525384A (zh) 2000-06-29 2009-09-09 艾博特公司 双特异性抗体及其制备方法和用途
WO2002011753A1 (fr) * 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Preparations proteiniques a injecter
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
HRP20050934B1 (hr) * 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
KR20070107079A (ko) * 2005-01-28 2007-11-06 와이어쓰 안정화된 액체 폴리펩타이드 제형
WO2006096461A2 (fr) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Compositions d'anticorps contre m-csf
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
PL2848258T3 (pl) 2005-10-26 2018-06-29 Novartis Ag Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta
CN201044845Y (zh) * 2006-10-28 2008-04-09 李开元 自动注射器
BRPI0721097A2 (pt) * 2006-12-11 2014-07-01 Hoffmann La Roche Formulação parenteral de anticorpo abeta
WO2008116103A2 (fr) * 2007-03-22 2008-09-25 Imclone Llc Formulations d'anticorps stables
EP2196476A1 (fr) * 2008-12-10 2010-06-16 Novartis Ag Formulation d'anticorps
WO2010100179A2 (fr) 2009-03-05 2010-09-10 Novartis Ag Système de gel autoformé pour administration de médicament à libération lente
WO2012028683A1 (fr) 2010-09-02 2012-03-08 Novartis Ag Système de gel d'anticorps pour administration de médicament prolongée

Also Published As

Publication number Publication date
DK3072906T3 (da) 2021-12-13
EP3072906B1 (fr) 2021-09-08
JP2026021446A (ja) 2026-02-10
SI2376533T1 (sl) 2016-07-29
US20120315285A1 (en) 2012-12-13
IL212922B (en) 2019-02-28
SMT201600222B (it) 2016-08-31
ES2900624T3 (es) 2022-03-17
US20110236398A1 (en) 2011-09-29
EP3792282A1 (fr) 2021-03-17
EP3072906A1 (fr) 2016-09-28
RU2011127913A (ru) 2013-01-20
JP2018168158A (ja) 2018-11-01
AU2009324371A1 (en) 2011-06-23
IL276622A (en) 2020-09-30
IL212922A0 (en) 2011-07-31
MY157772A (en) 2016-07-29
NZ592918A (en) 2012-12-21
US8623367B2 (en) 2014-01-07
PT3072906T (pt) 2021-12-14
RU2015132431A3 (fr) 2018-12-24
EP2376533B1 (fr) 2016-03-30
CN104399076A (zh) 2015-03-11
CN102245639B (zh) 2014-12-24
WO2010066762A1 (fr) 2010-06-17
CO6361952A2 (es) 2012-01-20
ECSP11011192A (es) 2011-08-31
PT2376533T (pt) 2016-07-13
AU2009324371B2 (en) 2013-10-10
TN2011000229A1 (en) 2012-12-17
KR20120009421A (ko) 2012-01-31
CA2745938A1 (fr) 2010-06-17
KR101762966B1 (ko) 2017-07-31
MY166050A (en) 2018-05-22
CL2011001406A1 (es) 2012-03-30
CN114225022A (zh) 2022-03-25
LT3072906T (lt) 2021-12-27
HRP20211899T1 (hr) 2022-03-04
CA2745938C (fr) 2018-04-24
IL264316B2 (en) 2024-01-01
CY1117735T1 (el) 2017-05-17
CN104399076B (zh) 2021-09-14
ZA201103362B (en) 2012-01-25
IL264316B1 (en) 2023-09-01
CN102245639A (zh) 2011-11-16
BRPI0922730A2 (en) 2018-11-06
KR20170044211A (ko) 2017-04-24
SI3072906T1 (sl) 2022-01-31
RU2563179C2 (ru) 2015-09-20
JP7286595B2 (ja) 2023-06-05
RU2015132431A (ru) 2018-12-24
EP2376533A1 (fr) 2011-10-19
US20200384108A1 (en) 2020-12-10
PL2376533T3 (pl) 2016-09-30
JP2012511540A (ja) 2012-05-24
IL264316A (en) 2019-02-28
JP2015231997A (ja) 2015-12-24
JP2020203889A (ja) 2020-12-24
EP2196476A1 (fr) 2010-06-16
HK1159130A1 (zh) 2012-07-27
CY1124844T1 (el) 2022-11-25
HRP20160754T1 (hr) 2016-08-12
MX2011006242A (es) 2011-06-24
HUE028408T2 (en) 2016-12-28
PE20120342A1 (es) 2012-04-24
HUE056626T2 (hu) 2022-02-28
JP2023109938A (ja) 2023-08-08
RU2745601C2 (ru) 2021-03-29
ES2579835T3 (es) 2016-08-17
PL3072906T3 (pl) 2022-01-24
JP6143416B2 (ja) 2017-06-07
DK2376533T3 (en) 2016-06-27

Similar Documents

Publication Publication Date Title
MA33023B1 (fr) Formulation d'anticorps
CY1123909T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r)
BR112015023391A8 (pt) formulações de conjugados anticorpo-droga anti-egfr
BR112012002080A2 (pt) formulações farmacêuticas estáveis altamente concentradas de um anticorpo anti-her2 farmaceuticamente ativo, uso de uma formulação, dispositivo de injeção e kit
HRP20060147B1 (hr) Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu
SV2010003517A (es) Anticuerpos anti-il-12/23 p40, epitopes, formulaciones, composiciones, metodos y usos "ref. cen5196svpct"
UA111825C2 (uk) Стабілізований препарат, що містить антитіло проти ngf
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
SV2006002174A (es) Composicion de anticuerpo her2
CL2008003537A1 (es) Compuestos derivados de 2-amino-pirimidina, antagonistas de receptores h4; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad alergica, inmunologica o inflamatoria o dolor.
CL2012001966A1 (es) Formulación farmacéutica que comprende entre 100-150 mg/ml de un anticuerpo que se une específicamente al receptor a de il-17 humana, una solución acuosa de un buffer 5-30 mm de ácido glutámico ph 4,5-5,2, prolina 2-4% p/v y polisorbato-20 0,005-0,02% p/v; envase farmacéutico y kit que comprende dicha formulación; y su uso para tratar psoriasis.
BRPI0908097A2 (pt) uso de pelo menos um composto, peptídeo, e, formulação farmacêutica.
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
EP2093237A4 (fr) Agent anticancéreux comprenant un anticorps anti-hb-egf en tant qu'ingrédient actif
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
BRPI0909296A2 (pt) uso de pelo menos um princípio ativo, e, composições cosmética, farmacêutica e/ou dermatológica
CL2012002948A1 (es) Formulación acuosa estable que comprende proteina almenos 5 mg/ml de proteina cd-rap y un aminoácido cargado.
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
CL2014003237A1 (es) Formulación farmacéutica estable que comprende un anticuerpo anti-dll4 (ligando tipo delta humano 4); y kit que comprende la composición en un envase e instrucciones.
MA55809A (fr) Formulation d'anticorps anti-il-6
TH121146A (th) สูตรผสมแอนติบอดี้
TR200806299A2 (tr) Çözünürlük artırıcı farmasötik formülasyon
TH138518A (th) การให้ในปริมาณที่กำหนดของ her แอนติบอดี้
TH0801002717B (th) สารต้านทานความเหนื่อยล้าและองค์ประกอบให้ทางปากที่ประกอบด้วยแอนโดรกราโฟไลด์ในรูปส่วนผสมออกฤทธิ์